Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2003-11-17
2008-10-21
Lucas, Zachariah (Department: 1648)
Chemistry: molecular biology and microbiology
Vector, per se
C536S023100, C536S023400, C536S023720, C435S235100, C435S236000, C435S239000, C435S325000
Reexamination Certificate
active
07439058
ABSTRACT:
Chimeric antigens derived from hepatitis B virus (HBV) and hepatitis C virus (HCV) are described which form virus-like particles when co-expressed with an excess of hepatitis B virus surface antigen (HBsAg). The chimeric antigens are fusion proteins containing an immunogenic peptide derived from an HCV protein coupled to the amino terminus of HBsAg. Also described are nucleic acid constructs and vectors for transfection of cells and expression of the chimeric antigens. The invention further provides methods for producing HBV/HCV virus-like particles containing the chimeric antigens, cell lines for producing the virus-like particles, combination vaccines containing the virus-like particles, and DNA vaccines that express the virus-like particles.
REFERENCES:
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 5098704 (1992-03-01), Valenzuela et al.
patent: 5292646 (1994-03-01), McCoy et al.
patent: 5324513 (1994-06-01), Sobczak et al.
patent: 5792463 (1998-08-01), Valenzuela et al.
patent: 5928902 (1999-07-01), De Wilde et al.
patent: 5942234 (1999-08-01), Ralston et al.
patent: 6096505 (2000-08-01), Selby et al.
patent: 6306625 (2001-10-01), Jacobs et al.
patent: 6890737 (2005-05-01), Maertens et al.
patent: 2003/0211996 (2003-11-01), Gowans et al.
patent: 2005/0220858 (2005-10-01), Bacon et al.
patent: 2005/0272097 (2005-12-01), Calenoff
patent: 0 201 416 (1986-11-01), None
patent: WO 93/06126 (1993-04-01), None
patent: WO 96/04301 (1996-02-01), None
Michalak et al., Journal of General Virology, vol. 78 No. 9, pp. 2299-2306 (Sep. 1997).
NCBI printour, GenBank Accession X02763, Hepatitis B Virus genome, (Sep. 1992).
NCBI printout, GenBank Accession M62321, Hepatitis V Virus polyprotein precursor (HCV-1) mRNA (Aug. 1993).
NCBI printout, GenBank Accession E01163, cDNA encoding human tissue plasminogen activator (Sep. 1997).
Chapman et al., Nucleic Acids Research, vol. 19 No. 14, pp. 3979-3986 (Jul. 1991).
Hartikka et al., Human Gene Therapy, vol. 7 No. 10, pp. 1205-1217 (Jun. 1996).
Simmonds et al., Journal of Clinical Microbiology, vol. 31 No. 6,pp. 1493-1503 (Jun. 1993).
Jackson et al., Journal of Medical Virology, vol. 51 No. 1, pp. 67-79 (Jan. 1997).
Choo et al., Proceedings of the National Academy of Sciences, U.S.A., colume 88 No. 6, pp. 2451-2455 (Mar. 1991).
Bowie et al., Deciphering the message in protein sequences: tolerance to amino acid substitutions, Science, vol. 247 No. 4948, pp. 1306-1310 (Mar. 1990).
Green et al., Potent T cell response to a class I-binding 13-mer viral epitope and the influence of HLA micropolymorphism in controlling epitope length, European Journal of Immunology, vol. 34 No. 9, pp. 2510-2519 (Sep. 2004).
Riffkin et al., A single amino-acid change between the antigenically different extracellular serine proteases V2 and B2 from Dichelobacter nodosus, Gene, vol. 167 Nos. 1-2, pp. 279-283 (Dec. 1995).
Martínez-Salas, Internal ribosome entry site biology and its use in expression vectors, Current Opinion in Biotechnology, vol. 10 No. 5, pp. 458-464 (Oct. 1999).
Mountford et al., Dicistronic targeting constructs: REporters and modifiers of mammalian gene expression, Proceedings of the National Academy of Sciences, vol. 91 No. 10, pp. 4303-4307 (May 1994).
Pizzato et al., Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer, Gene Therapy, vol. 5 No. 7, pp. 1003-1007 (Jul. 1998).
Cardoso et al., “Isolation and characterization of human monoclonal antibodies against hepatitis C virus envelope glycoproteins,” Journal of Medical Virology, vol. 55 No. 1, pp. 28-34 (May 1998).
Esumi et al., “Murine Antibodies against E2 and Hypervariable Region 1 Cross-Reactively Capture Hepatitis C Virus,” Virology, vol. 251 No. 1, pp. 158-164 (Nov. 1998).
Esumi et al., “Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees,” Archives of Virology, vol. 144 No. 5, pp. 973-980 (May 1999).
Fournillier et al., “Expression of Noncovalent Hepatitis C Virus Envelope E1-E2 Complexes Is Not Required for the Induction of Antibodies with Neutralizing Properties following DNA Immunization,” Journal of Virology, vol. 73 Np. 9, pp. 7497-7504 (Sep. 1999).
Golden et al., Protein Expression and Purification, vol. 14 No. 1, pp. 8-12 (Oct. 1998).
Flint et al., Journal of Virology, col. 73 No. 8, pp. 6782-6790 (Aug. 1999).
Ono et al., Nucleic Acids REsearch, vol. 11 No. 6, pp. 1747-1757 (1983).
Delpeyroux et al., “Structural Factors Modulate the Activity of Antigenic Poliovirus Sequences Expressed on Hybrid Hepatitis B surface Antigen Particles,”J. Virol. 64(12):6090-6100 (1990).
Delpeyroux et al., “Presentation and immunogenicity of the hepatitis B surface antigen and a poliovirus neutralization antigen on mixed emplt ebvelope particles”,J. Virol. 62(5):1836-1839 (1998).
Inchauspé et al., “DNA Vaccination for the Induction of Immune Responses Against Hepatitis C Virus Proteins,”Vaccine 15(8):853-856 (1997).
Inchauspé et al., “Immune Responses Against Hepatitis C Virus Structural Proteins Following Genetic Immunization,”Dev. Biol. Stand. 92:163-168 (1998).
Lee et al., “Presentation of the hydrophilic domains of hepatitis C viral E2 envelope glycoprotein on hepatitis B surface antigen particles,”Journal of Medical Virology 50:145-151 (1996).
Lee et al., “Characterization of a New Genotype II Hepatitis Delta Virus from Taiwan,”Journal of Medical Virology 49:145-154 (1996).
Major et al., “DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid,”Journal of Virology 69(9):5798-5805 (1995).
Nakano et al., “Immunization with Plasmid DNA Encoding Hepatitis C Virus Envelope E2 Antigenic Domains Induces Antibodies Whose Immune Reactivity is Linked to the Injection Mode,”Journal of Virology 71(9):7101-7109 (1997).
Valenzuela et al., “Antigen Engineering in Yeast: Synthesis and Assembly of Hybrid Hepatitis B Surface Antigen-Herpes Simplex 1 gD Particles,”Bio/Technology 3:323-326 (1985).
Glazer Edward
Houghton Michael
Selby Mark
Lucas Zachariah
Novartis Vaccines and Diagnostics Inc.
Robins Roberta L.
Seka Mark
LandOfFree
HBV/HCV virus-like particle does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HBV/HCV virus-like particle, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HBV/HCV virus-like particle will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3996219